Clinical Trials Browser

Phase 2 × Alemtuzumab × 1 year × Clear all

NCT06084780 2026-01-23

TRANSCAPE

Phase 2 Not yet recruiting

Pseudomyxoma Peritonei

NCT01361711 2025-05-23

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Phase 2 Active not recruiting

53 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell